Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
Poster Number | Title & Presenter | Dates | ||
40 | Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
| NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
Title | Title & Presenter | Dates | ||
Sponsored Symposia | NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
| NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis®ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Contact information
Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678
Media Contact:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seglan Payments Solution Provider Turns to Verimatrix for Efficient, Time-Tested Security24.2.2021 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Seglan, an existing Verimatrix Code Protection customer and leading provider of secure payment solutions, recently selected the Verimatrix Mobile Payments technology to provide global banks and processors with time-trusted security. Seglan previously developed their own mobile payment Software Developer Kit (SDK) for implementation across its customer base. It’s now in the process of deploying Verimatrix’s mobile payments SDK that offers existing certifications for streamlining Seglan’s go-to-market capabilities aimed at some of the largest financial institutions in Europe and South America. The Verimatrix security tool will continue to be used for Seglan’s 3DSecure SDKs (certification included) while also aiming to provide their customers a full HCE and 3DSecure solution all contained within a single server. “Having successfully relied upon Ve
EnTrust Global’s Julian Proctor to Present at Economist’s World Ocean Summit24.2.2021 17:02:00 CET | Press release
Julian Proctor, Portfolio Manager of EnTrust Global’s Blue Ocean 4Impact Fund (“BO 4Impact”), will join Elisabeth Munck af Rosenschöld, Head of Supply Chain and Sustainability at IKEA, Sadan Kaptanoglu, President of BIMCO, Jeremy Nixon, Chief Executive of Ocean Network Express Co., and Craig Jasienski, Group Chief Executive at Wallenius Wilhelmsen at The Economist’ World Ocean Summit panel entitled “Shipping: Collaborating across industry and supply chains to reduce emissions.” Blue Ocean 4Impact is part of EnTrust Global’s $2+ billion maritime investment platform and is launching one of the first companies that will own and lease environmentally-advanced vessels and other marine infrastructure assets to large corporate operators and end-users, in order to help reduce carbon emissions and other pollution generated by the ocean economy. The Summit is the pre-eminent global event bringing together the widest cross-section of ocean stakeholders each year, from business to government to ci
New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection24.2.2021 17:00:00 CET | Press release
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology. The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes. The study results lend support for Zio as a screening tool for early detection of AF. The results have important implications for stroke prevention, especially as the pre
Jamestown Expands European Presence With More Than $1 Billion in Assets Under Management24.2.2021 16:22:00 CET | Press release
Global real estate and investment company Jamestown today announced it has significantly expanded its global presence and now has more than $1 billion in European assets under management with the acquisition of another two buildings in Amsterdam, and a mandate to manage a portfolio of properties across Europe on behalf of one of its institutional investment partners and co-investors, E.ON Pension Trust. This latest news about its European portfolio comes on the heels of Jamestown’s recent purchase of three office buildings in Cologne, Germany, and just over a year after purchasing the iconic Groot Handelsgebouw in Rotterdam, one of the largest mixed-use buildings in the Netherlands, which currently houses more than 450 businesses. “After entering the European market just over a year ago, Jamestown has grown its platform with $1 billion in assets under management and a knowledgeable real estate team headquartered in Cologne, Germany and offices in Amsterdam, London, and Madrid,” said Ja
Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion24.2.2021 16:00:00 CET | Press release
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/ VueLife® "HP" Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire) T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients. Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorpo
KA Imaging to Present Poster on Unprecedented Lateral Dual-Energy X-ray Views at ECR 202124.2.2021 15:17:00 CET | Press release
KA Imaging, a company that develops innovative X-ray imaging solutions, announced that a poster reporting on results from a study examining the feasibility of lateral chest dual-energy subtraction radiography using a stacked single-exposure multi-layer x-ray detectorwill be presented by Sebastian Maurino, a medical physicist at KA Imaging, at this year’s European Congress of Radiology (ECR). As highlighted in the poster, KA Imaging’s novel approach allows radiologists to take full advantage of lateral dual-energy images by obtaining both conventional and dual-energy subtraction lateral images simultaneously, thereby making it considerably easier to differentiate between materials behind the heart. Quoting directly from the poster, “The DE lateral image also visualizes calcified joints and masses behind the heart that are not visible in the [Posterior-Anterior (PA)] image. Multi-layer detectors were shown to provide DE PA and lateral images of the chest at conventional patient dose leve
OAG and IATA Strengthen Data Partnership to Combat Market and Schedule Volatility24.2.2021 15:00:00 CET | Press release
OAG, the world’s leading provider of travel data and insight has agreed a partnership with International Air Transport Association (IATA), to provide schedule and reference data via its new cloud platform. As part of the strengthened partnership between the two aviation leaders, OAG will also provide IATA with a customized version of its market-leading Analyzer tool which will be offered as part of a bundle alongside Airport IS and other existing tools in the future. Built on the Snowflake cloud platform, the supply of reference and schedules data provides customers with the richest and freshest version of schedules data available in the market. “COVID-19’s ongoing impact on traffic volatility has made it critical to power our products with the most up-to-date data available,” said Charles de Gheldere, Director Aviation Data at IATA. “Our strengthened partnership with OAG supplies our airport customers with fresh and accurate data and a highly-innovative, modern and flexible cloud-base
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom